Long Way Education

By longwayeducation.com

A group of pharmacy students wrote this article. They like searching for and writing about diseases and new research on their treatment.

This article discusses the different types of therapeutic cancer vaccines, their mechanisms, progress in clinical trials, and future challenges and directions in the field.

Cancer

Cancer remains one of the leading causes of mortality worldwide, characterized by the uncontrolled growth and spread of cells with mutated DNA. Standard treatments like chemotherapy, radiation, and surgery have advanced, but their side effects and lack of effectiveness have led to the search for new therapeutic alternatives.

For example, therapeutic cancer vaccines are a promising alternative that uses the body’s immune system to directly target and destroy cancer cells. In contrast to preventive vaccinations, therapeutic cancer vaccines aim to treat existing cancer and are often used in combination with other treatments to increase their effectiveness.

Let’s delve deeper into exploring this dangerous disease, current cancer treatment vaccines, and recent developments.

How Cancer Develops

Cancer development involves a complex process that is usually explained by the three-stage theory of cancer:

1. Initiation: Cells undergo mutations from carcinogen exposure or spontaneously, affecting oncogenes and tumor suppressor genes, leading to uncontrolled division.
2. Promotion: Mutated cells are stimulated to divide by environmental factors, requiring repeated exposure to stimuli such as estrogen.
3. Progression: Tumor cells compete for resources, leading to further mutations and increased heterogeneity, complicating diagnosis and treatment.

Did You Know?

Hormones like progesterone and estrogen have an impact on certain forms of breast cancer. Estrogen and progesterone bind to receptors (proteins) on breast cancer cells, promoting their growth. Treatments that block these hormones from attaching to these receptors are called hormone therapy. To learn more about the therapeutic role of hormones, visit Hormone Therapy for Breast Cancer.

Cancer Risk Factors

Biological factors such as:

• Age and genetics cannot be controlled.

Modifiable factors include:

• Diet,
• Tobacco use,
• Exposure to carcinogens such as ultraviolet radiation and some viruses.

How Cancer Cells Affect Our Immune System

T and B cells react to cancer antigens as part of adaptive immunity. B cells target antigens on cancer cell surfaces and produce antibodies that inhibit tumor growth. T cells recognize peptides from intracellular proteins presented on major histocompatibility complex (MHC) molecules. There are two main types of T cells involved:

1. CD8 T cells (killer T cells) recognize antigens presented by MHC class I molecules.
2. CD4 T cells (helper T cells) recognize antigens presented by MHC class II molecules.

Both cell types have receptors that bind to specific epitopes necessary for their activation and proliferation.

Immune Release Theory

Immunomodulation explains how normal cells turn into detectable cancer through three stages:

1. Elimination: The immune system destroys early tumors.
2. Equilibrium: Some cancer cells survive and enter a dormant state, perhaps developing into resistant forms.
3. Escape: Cancer cells avoid detection by the immune system and proliferate, aided by mechanisms such as decreased recognition or immunosuppression in the tumor environment.

Immunotherapies

Conventional treatments such as surgery and chemotherapy are often of limited effectiveness, highlighting the need for improved options. Therapeutic cancer vaccines aim to stimulate T cells against tumors. Although challenges remain, progress in identifying new antigens holds promise for advancing immunotherapy.

Types of Therapeutic Vaccines

1. Tumor Cell Vaccines

• Autologous Cancer Cell Vaccines: These are made from the patient’s tumor cells. These cells are usually irradiated to weaken them and mixed with immune boosters such as Bacillus Calmette-Guérin to enhance the immune targeting of tumors.
• Allogenic Cancer Cell Vaccines: Derived from two or three established cancer cell lines and offer standardized production and cost-effectiveness. Examples include Canvaxin™ and GVAX.

2. Dendritic Cell Vaccines

These cells present various tumor antigens to T cells, enhancing immune responses. Improving dendritic cell maturation and delivery methods can induce robust CD4+ and CD8+ T cell responses.

3. Peptide-based Cancer Vaccines

Synthetic long peptide (SLP) vaccines enhance T-cell activation by presenting multiple tumor-derived epitopes to antigen-presenting cells. They improve peptide stability and delivery but face challenges such as complex preparation and limitations due to certain human leukocyte antigen (HLA) types, which can limit patient responses.

4. DNA Vaccines

DNA vaccines use bacterial plasmids to deliver tumor antigens to antigen-presenting cells. Once inside, the plasmid DNA is transcribed and translated, producing tumor antigens presented on MHC molecules. This activates CD8+ T cells, which target and kill cancer cells presenting these antigens, while CD4+ T cells support the immune response.

5. RNA Vaccines

MRNA vaccines work by delivering tumor-specific mRNA into cells. This mRNA directs the cells to produce tumor antigens, which are then presented on their surfaces. The immune system recognizes these antigens as strangers, activating cytotoxic T lymphocytes (CTLs) to target and destroy cancer cells.

6. Viral and Bacterial Vector Vaccines

Modified viruses or bacteria deliver tumor antigens, helping the immune system recognize and attack cancer cells, primarily activating CD8+ cytotoxic T cells.

Did You Know?

The immune system is responsible for defending the body. It prevents illness and speeds recovery from injuries and illnesses. You can strengthen your immune system by eating well, exercising, and getting enough sleep.

Current Therapeutic Cancer Vaccines and Recent Developments

Therapeutic cancer vaccines are intended to treat existing cancers by activating the immune system to target cancer cells specifically. In contrast to preventive vaccines (such as HPV vaccines, which lower the risk of some cancers), therapeutic vaccines strengthen the immune system so that they can directly target cancer cells. Examples of therapeutic cancer vaccines, including their approvals, cancer targets, and mechanisms of action, include:

Successful therapeutic cancer vaccines:

1. Provenge (Sipuleucel-T): Provenge received FDA approval in the United States in 2010 for the treatment of metastatic castration-resistant prostate cancer. It works by collecting the patient’s immune cells and priming them outside the body to selectively target prostate cancer cells. When these cells are reintroduced into the patient, they induce an immune response against cancer. Provenge has a minor survival advantage and is usually used in the late stages of prostate cancer.
2. Talimogene laherparepvec (T-VEC or Imlygic): Talimogene laherparepvec, also known as T-VEC, received FDA approval in the United States in 2015 and is also approved in Europe for treating metastatic melanoma. The treatment uses a genetically modified herpes simplex virus that replicates specifically inside melanoma cells, causing cancer cells to die. T-VEC not only kills cancer cells directly, but it also stimulates immune responses that help target melanoma throughout the body.
3. CG (Bacillus Calmette-Guérin): BCG was licensed by the FDA in 1990 to treat non-muscle-invasive bladder cancer. It is injected directly into the bladder, activating a localized immune response that aids in destroying cancer cells. BCG is considered the standard treatment for early-stage bladder cancer, with particular efficacy for carcinoma in situ.
4. CimaVax-EGF: It is approved in Cuba and numerous other countries. It is currently being tested in the United States for non-small cell lung cancer (NSCLC). This vaccine targets epidermal growth factor (EGF) and reduces its levels in the bloodstream to prevent or stop cancer growth. CimaVax is commonly used as a maintenance therapy in NSCLC to help improve patient survival.
   
5. OncoVAX: The OncoVAX vaccine has been approved in some European countries for treating stage II colon cancer and is being tested for treating other types of malignancy. The vaccine is made from irradiated autologous tumor cells, which are later reintroduced into the patient to stimulate an immune response to colorectal cancer. The OncoVAX vaccine is intended to reduce the recurrence of cancer after surgery.
   

Promising cancer vaccines under development:

1. DCVaxL is intended to treat glioblastoma, a kind of brain cancer, by training the patient’s immune system to recognize and attack the tumor. This personalized strategy increases patient survival, and DCVax-L has demonstrated promising outcomes in late-stage clinical trials.
2. NeoVax is a vaccine designed to specifically target melanoma and other cancers by focusing on the unique mutations or neoantigens present in each patient’s cancer. This personalized approach has been successful in clinical trials, especially when paired with other immunotherapies to boost efficacy.
3. IMA901 takes a multi-antigen strategy to treat kidney cancer, incorporating various cancer-specific antigens that trigger immune cells to attack the tumor. Although IMA901 has shown early efficacy, it is presently being studied with other medications to enhance results even more.

Challenges and Limitations

1. Efficiency and Safety

The main challenge associated with therapeutic cancer vaccines concerns their efficacy. The recognition of cancerous cells through the action of the immune system and the targeting of such cells are impeded by mechanisms including immune suppression and tumor heterogeneity. In addition, the potencies of vaccines usually must be enhanced through strong adjuvants, which may present safety risks.

2. Patient Variability

Different immune responses from patient to patient may alter treatment outcomes. Predicting inconsistent outcomes in individual patients regarding vaccine efficacy may also be challenging due to patient variability.

3. Manufacturing and Cost

Adding to the complexity of production and accessibility issues is that therapeutic cancer vaccines are still out of reach for people in general. The manufacturing process is so complex and expensive that mass production of vaccines is difficult.

Future Directions of Therapeutic Cancer Vaccines’ Efficacy

• Advances in research are expected to see further personalization, with more genetic and protein profiles being used to create highly personalized vaccines.
• Continuous improvement of adjuvants and delivery methods to enhance immune responses while minimizing adverse effects has improved safety and efficacy.
• Integrate digital health by leveraging digital tools to monitor patient responses and adapt treatment in real-time.

Companies Researching Cancer Vaccines

• BioNTech, founded in Germany, is best known for its cancer research and treatment development work. The company’s entry into cancer vaccine development could revolutionize oncology research in phase I and II clinical trials, which are being conducted to treat a variety of cancers, including advanced melanoma, prostate cancer, and ovarian cancer. Lots of these trials are categorized as cell therapies, mRNA-based platforms, and antibodies.
• Bristol-Myers Squibb (BMS), a US company with a subsidiary in the UAE, is developing several therapeutic cancer vaccines through its Immunology division, focusing on combining vaccines with existing immunotherapies.
• Moderna, an American company known for its mRNA technology, is developing personalized cancer vaccines based on nanoantigens. Its strategy uses mRNA to stimulate an immune response targeting tumor cells.

Conclusion

Therapeutic cancer vaccines are a new area of oncology that could transform cancer treatment by targeting and effectively utilizing the immune system to fight cancers. Despite tremendous improvement, obstacles such as vaccination effectiveness, patient variability, and high manufacturing costs persist. Advances in personalization through genetic profiling and advancements in adjuvants and delivery systems are expected to increase the efficacy and safety of vaccinations. Therapeutic cancer vaccines, with continued research, collaboration, and technology developments, have the potential to revolutionize the landscape of cancer treatment, giving patients new hope.

Sources

• Cancer. (2011). Toxipedia. Retrieved October 16, 2024, https://www.healthandenvironment.org/docs/ToxipediaCancerPageArchive.pdf
• Overview of cancer. (n.d.). Your Guide to Cancer Prevention: Sample Chapter.
• The causes of cancer. (n.d.). IARC Publications. Retrieved October 10, 20244, https://publications.iarc.fr/_publications/media/download/4097/52fc753d9c7ce5ff141c6a1dc5424cf3c6cf0df4.pdf.
• The Cancer Epitope Database and Analysis Resource (CEDAR). (2022, October 17). NAR Breakthrough Article.
• Immuno-oncology Theories: Immunoediting and Immune Surveillance.
• Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023). Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal transduction and targeted therapy.
• Guo, C., Manjili, M. H., Subjeck, J. R., Sarkar, D., Fisher, P. B., & Wang, X. (2013). Therapeutic cancer vaccines: past, present, and future. Europe PMC (PubMed Central), 119, 421–475.
• McKarney I. (2007). Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer. Issues in emerging health technologies, (101), 1–4.
• Grigg, C., Blake, Z., Gartrell, R., Sacher, A., Taback, B., & Saenger, Y. (2016). Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
• Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022). Cancer vaccines as promising immunotherapeutics: platforms and current progress. Journal of Hematology & Oncology, 15(1), 28.
• Plotkin SA, Orenstein WA, Offit PA, Edwards KM. Plotkin’s Vaccines. 8th ed. Amsterdam: Elsevier; 2023.
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684.
• Guo C, Manjili MH, Subjeck JR, et al. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421–475. doi:10.1016/B978-0-12-407190-2.00007-1.
• Cancer vaccines: 10 biotech companies that have changed the game.
• Therapeutic Cancer Vaccines: Current Status and Moving Forward.

© Long Way Education, 2024

Latest Posts

• The History of Wool
• Forests: Importance, Threats, and Conservation
• Textile Fibers: Definition, Classification, and Types
• Tie-Dye Techniques and Process: A Guide to Spiral-Pattern T-Shirts
• The Art of Batik: Traditional Types, Techniques, and Process

LongWayEducation

The Long Way Education Site path is based on self-learning. Here, you will learn about science, education, and religion. You will also learn about fiber and its manufacture. And different disciplines of engineering, such as mechanical and industrial engineering.